Comparative Pharmacology
Head-to-head clinical analysis: DEAPRIL ST versus UNIVASC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEAPRIL ST versus UNIVASC.
DEAPRIL-ST vs UNIVASC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme (ACE) inhibitor. Inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Oral: 2.5 mg twice daily, titrated up to 5 mg twice daily as tolerated. Maximum dose: 10 mg daily.
Initial: 7.5 mg orally once daily; titrate to 15-30 mg once daily. Maximum: 60 mg/day.
None Documented
None Documented
8-10 hours; prolonged in renal impairment (up to 24 hours in severe cases)
The terminal elimination half-life of moexiprilat, the active metabolite, is approximately 9.8 hours in patients with normal renal function. This supports once-daily dosing, though the antihypertensive effect may persist beyond 24 hours with continued therapy.
Renal (90% as unchanged drug), biliary/fecal (10%)
Univasc (moexipril) is primarily eliminated via renal excretion (approximately 50% of absorbed dose as unchanged drug and metabolites) and fecal excretion (about 50%).
Category C
Category C
ACE Inhibitor
ACE Inhibitor